Sarah F. Andrews
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sarah F. Andrews has a total of 616 co-authors. Here are the top co-authors by number of shared publications:
- Adrian B. McDermott
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA
19 shared publications - Masaru Kanekiyo
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
14 shared publications - Rebecca A. Gillespie
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
10 shared publications - Adrian Creanga
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA
8 shared publications Grace L. Chen
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20902, USA
7 shared publicationsJohn R. Mascola
Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, USA
7 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by Wiley in Immunological Reviews
- Vol. 341 (1) , e70164
The Influenza‐Specific Immunoglobulin Repertoire – Nimble Yet Steeped in Tradition
Influenza virus has circulated in the human population and co‐evolved with us for centuries or longer, shaping our immune repertoires through a continuous host–virus arms race. Across individuals, antibodies repeatedly converge on shared solutions for capturing this shape‐shifting virus by precisely targeting conserved sites of vulnerability—sites the virus cannot alter without functional cost—through structural features encoded directly by germline immunoglobulin genes. These recurring public antibodies, termed multi‐donor class antibodies, have been pivotal for understanding human anti‐influenza immunity and in guiding vaccine strategies that may shift the balance of the host–virus arms race. As single‐cell biology, structural biology, and computational approaches mature, previously uncharted areas of our immune repertoires are coming into view. Here, we review the current understanding of the influenza‐specific immune repertoire, focusing on antibodies and multi‐donor antibody classes directed toward antigenic supersites on viral hemagglutinin and neuraminidase—the two major targets of protective antibodies—and discuss how these insights may advance the development of game‐changing influenza vaccines.
- 25 August 2026
- Published by Wiley in Immunological Reviews
- Vol. 341 (1) , e70164
Open AccessThe Influenza‐Specific Immunoglobulin Repertoire – Nimble Yet Steeped in Tradition
Influenza virus has circulated in the human population and co‐evolved with us for centuries or longer, shaping our immune repertoires through a continuous host–virus arms race. Across individuals, antibodies repeatedly converge on shared solutions for capturing this shape‐shifting virus by precisely targeting conserved sites of vulnerability—sites the virus cannot alter without functional cost—through structural features encoded directly by germline immunoglobulin genes. These recurring public antibodies, termed multi‐donor class antibodies, have been pivotal for understanding human anti‐influenza immunity and in guiding vaccine strategies that may shift the balance of the host–virus arms race. As single‐cell biology, structural biology, and computational approaches mature, previously uncharted areas of our immune repertoires are coming into view. Here, we review the current understanding of the influenza‐specific immune repertoire, focusing on antibodies and multi‐donor antibody classes directed toward antigenic supersites on viral hemagglutinin and neuraminidase—the two major targets of protective antibodies—and discuss how these insights may advance the development of game‐changing influenza vaccines.
- 10 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (853) , eaeb9847
SARS-CoV-2 variant booster vaccination and infection alter the breadth of the memory B cell repertoire
Evolving endemic viruses such as influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain major health threats. Although variant updated vaccines aim to enhance protection, preexisting immunity shapes memory B cell (MBC) responses. To assess how SARS-CoV-2 spike protein variant–based vaccine boosters and infections alter the MBC repertoire, we analyzed MBC responses in the COVAIL vaccine trial, where participants previously vaccinated with SARS-CoV-2 Wuhan-1 spike immunogen were boosted with Wuhan-1, variant, or bivalent spike immunogens. Some participants also experienced a subsequent infection with an Omicron variant. We determined that variant vaccine boosters and SARS-CoV-2 infections led to transiently greater recall of cross-reactive MBCs compared with a Wuhan-1 vaccine booster. Long term, we detected little change in the MBC repertoire after an Omicron vaccine booster, but MBCs evaluated several months after Omicron variant infection had higher neutralization capacity to both Wuhan-1 and BA.1 compared with those from individuals who had not experienced an infection. However, these Wuhan-1/BA.1 cross-reactive MBCs from infected individuals displayed less breadth toward the more distant BA.2.86 lineage than MBCs from uninfected individuals. Thus, SARS-CoV-2 variant boosters and infections differentially shape the long-term MBC repertoire.
- 10 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (853) , eaeb9847
SARS-CoV-2 variant booster vaccination and infection alter the breadth of the memory B cell repertoire
Evolving endemic viruses such as influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain major health threats. Although variant updated vaccines aim to enhance protection, preexisting immunity shapes memory B cell (MBC) responses. To assess how SARS-CoV-2 spike protein variant–based vaccine boosters and infections alter the MBC repertoire, we analyzed MBC responses in the COVAIL vaccine trial, where participants previously vaccinated with SARS-CoV-2 Wuhan-1 spike immunogen were boosted with Wuhan-1, variant, or bivalent spike immunogens. Some participants also experienced a subsequent infection with an Omicron variant. We determined that variant vaccine boosters and SARS-CoV-2 infections led to transiently greater recall of cross-reactive MBCs compared with a Wuhan-1 vaccine booster. Long term, we detected little change in the MBC repertoire after an Omicron vaccine booster, but MBCs evaluated several months after Omicron variant infection had higher neutralization capacity to both Wuhan-1 and BA.1 compared with those from individuals who had not experienced an infection. However, these Wuhan-1/BA.1 cross-reactive MBCs from infected individuals displayed less breadth toward the more distant BA.2.86 lineage than MBCs from uninfected individuals. Thus, SARS-CoV-2 variant boosters and infections differentially shape the long-term MBC repertoire.
- 25 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (838) , eaeb9837
The vaccine platform used for COVID-19 primary immunization shapes the quality of the human B cell response to a vaccine boost
Improving long-term protective immunity elicited by prime-boost vaccinations requires a deeper understanding of the immunologic outcomes of different vaccine platforms. Given the variety of platforms used to develop vaccines against SARS-CoV-2, we reasoned that SARS-CoV-2 offered an opportunity to compare vaccine platforms in humans. We used flow cytometry and single-cell transcriptomics to explore the B cell response to different homologous and heterologous vaccine regimens. We found that an adenovirus vector prime followed by a messenger RNA (mRNA) vaccine boost showed the greatest short-term B cell expansion and preferentially elicited an activated atypical B cell subset that was associated with antibody binding titers against spike protein. In contrast, an mRNA primary series followed by homologous boost induced a different activated B cell subset with more proliferative potential and high frequencies of a long-lived resting memory subset. Moreover, immunoglobulin A (IgA)–expressing memory B cells had more somatic hypermutations than the predominant IgG-expressing B cell population. This heterogeneity in vaccine-elicited B cell responses underscores the potential of tailoring vaccine regimens that combine different platforms to achieve potent and durable protection against infectious diseases.
- 25 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (838) , eaeb9837
The vaccine platform used for COVID-19 primary immunization shapes the quality of the human B cell response to a vaccine boost
Improving long-term protective immunity elicited by prime-boost vaccinations requires a deeper understanding of the immunologic outcomes of different vaccine platforms. Given the variety of platforms used to develop vaccines against SARS-CoV-2, we reasoned that SARS-CoV-2 offered an opportunity to compare vaccine platforms in humans. We used flow cytometry and single-cell transcriptomics to explore the B cell response to different homologous and heterologous vaccine regimens. We found that an adenovirus vector prime followed by a messenger RNA (mRNA) vaccine boost showed the greatest short-term B cell expansion and preferentially elicited an activated atypical B cell subset that was associated with antibody binding titers against spike protein. In contrast, an mRNA primary series followed by homologous boost induced a different activated B cell subset with more proliferative potential and high frequencies of a long-lived resting memory subset. Moreover, immunoglobulin A (IgA)–expressing memory B cells had more somatic hypermutations than the predominant IgG-expressing B cell population. This heterogeneity in vaccine-elicited B cell responses underscores the potential of tailoring vaccine regimens that combine different platforms to achieve potent and durable protection against infectious diseases.
- Open Access
- 14 October 2025
- Published by Springer Nature in Nature Microbiology
- Vol. 10 (11) , 2903-2918
Cross-neutralizing and potent human monoclonal antibodies against historical and emerging H5Nx influenza viruses
Highly pathogenic avian influenza H5Nx viruses are an emerging threat for global health, especially clade 2.3.4.4b H5N1 virus which causes panzootic infections. Here we describe the isolation and characterization of broadly cross-neutralizing monoclonal antibodies (mAbs) against diverse H5Nx viruses from individuals who received a monovalent H5N1 vaccine 15 years ago. By screening over 500 mAbs, we identified 5 mAbs that neutralized the majority of H5 clades including 2.3.4.4b and target three distinct conserved epitopes within the HA globular head. Cryo-electron microscopy structures of these mAbs in complex with HA, deep mutational scanning and neutralization escape studies define the sites of vulnerability of H5 HA. These mAbs mediated stronger prophylactic protection against clade 2.3.4.4b H5N1 infection in mice than the best-in-class mAb targeting the HA stem. Our study identified several highly potent broadly neutralizing H5 mAbs from humans that either alone or in combination provide a pragmatic pandemic preparedness option against the threat of panzootic H5N1 influenza.
- 14 October 2025
- Published by Springer Nature in Nature Microbiology
- Vol. 10 (11) , 2903-2918
Open AccessCross-neutralizing and potent human monoclonal antibodies against historical and emerging H5Nx influenza viruses
Highly pathogenic avian influenza H5Nx viruses are an emerging threat for global health, especially clade 2.3.4.4b H5N1 virus which causes panzootic infections. Here we describe the isolation and characterization of broadly cross-neutralizing monoclonal antibodies (mAbs) against diverse H5Nx viruses from individuals who received a monovalent H5N1 vaccine 15 years ago. By screening over 500 mAbs, we identified 5 mAbs that neutralized the majority of H5 clades including 2.3.4.4b and target three distinct conserved epitopes within the HA globular head. Cryo-electron microscopy structures of these mAbs in complex with HA, deep mutational scanning and neutralization escape studies define the sites of vulnerability of H5 HA. These mAbs mediated stronger prophylactic protection against clade 2.3.4.4b H5N1 infection in mice than the best-in-class mAb targeting the HA stem. Our study identified several highly potent broadly neutralizing H5 mAbs from humans that either alone or in combination provide a pragmatic pandemic preparedness option against the threat of panzootic H5N1 influenza.
- 10 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (815) , eady3570
Functional, immunogenetic, and structural convergence in influenza immunity between humans and macaques
Human B cell immunity to the influenza hemagglutinin (HA) stem, a universal vaccine target, is often stereotyped and immunogenetically restricted, posing hurdles to study outside of humans. Here, we show that cynomolgus macaques vaccinated with an HA stem immunogen elicit humanlike public B cell lineages targeting two major conserved sites of vulnerability, the central stem and anchor epitopes. Central stem antibodies were predominantly derived from V H 1-138, the macaque homolog of human V H 1-69, a V H gene preferentially used in human central stem broadly neutralizing antibodies (bnAbs). Similarly, macaques produced anchor bnAbs containing the canonical NWP motif. Both bnAb lineages were functionally and structurally analogous to their human counterparts, with recognition mediated largely by germline-encoded structural motifs. These findings indicate that the macaque immunoglobulin repertoire can support humanlike public bnAb responses to influenza HA, highlighting the value of the macaque model for translational vaccinology. Moreover, this underscores the utility of homologous germline-encoded immunity, suggesting that immune repertoires of macaques and humans have been similarly shaped during evolution.
- 10 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (815) , eady3570
Functional, immunogenetic, and structural convergence in influenza immunity between humans and macaques
Human B cell immunity to the influenza hemagglutinin (HA) stem, a universal vaccine target, is often stereotyped and immunogenetically restricted, posing hurdles to study outside of humans. Here, we show that cynomolgus macaques vaccinated with an HA stem immunogen elicit humanlike public B cell lineages targeting two major conserved sites of vulnerability, the central stem and anchor epitopes. Central stem antibodies were predominantly derived from V H 1-138, the macaque homolog of human V H 1-69, a V H gene preferentially used in human central stem broadly neutralizing antibodies (bnAbs). Similarly, macaques produced anchor bnAbs containing the canonical NWP motif. Both bnAb lineages were functionally and structurally analogous to their human counterparts, with recognition mediated largely by germline-encoded structural motifs. These findings indicate that the macaque immunoglobulin repertoire can support humanlike public bnAb responses to influenza HA, highlighting the value of the macaque model for translational vaccinology. Moreover, this underscores the utility of homologous germline-encoded immunity, suggesting that immune repertoires of macaques and humans have been similarly shaped during evolution.
- Open Access
- 1 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Structural convergence and water-mediated substrate mimicry enable broad neuraminidase inhibition by human antibodies
Influenza has been responsible for multiple global pandemics and seasonal epidemics and claimed millions of lives. The imminent threat of a panzootic outbreak of avian influenza H5N1 virus underscores the urgent need for pandemic preparedness and effective countermeasures, including monoclonal antibodies (mAbs). Here, we characterize human mAbs that target the highly conserved catalytic site of viral neuraminidase (NA), termed NCS mAbs, and the molecular basis of their broad specificity. Cross-reactive NA-specific B cells were isolated by using stabilized NA probes of non-circulating subtypes. We found that NCS mAbs recognized multiple NAs of influenza A as well as influenza B NAs and conferred prophylactic protections in mice against H1N1, H5N1, and influenza B viruses. Cryo-electron microscopy structures of two NCS mAbs revealed that they rely on structural mimicry of sialic acid, the substrate of NA, by coordinating not only amino acid side chains but also water molecules, enabling inhibition of NA activity across multiple influenza A and B viruses, including avian influenza clade 2.3.4.4b H5N1 viruses. Our results provide a molecular basis for the broad reactivity and inhibitory activity of NCS mAbs targeting the catalytic site of NA through substrate mimicry.
- 1 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Open AccessStructural convergence and water-mediated substrate mimicry enable broad neuraminidase inhibition by human antibodies
Influenza has been responsible for multiple global pandemics and seasonal epidemics and claimed millions of lives. The imminent threat of a panzootic outbreak of avian influenza H5N1 virus underscores the urgent need for pandemic preparedness and effective countermeasures, including monoclonal antibodies (mAbs). Here, we characterize human mAbs that target the highly conserved catalytic site of viral neuraminidase (NA), termed NCS mAbs, and the molecular basis of their broad specificity. Cross-reactive NA-specific B cells were isolated by using stabilized NA probes of non-circulating subtypes. We found that NCS mAbs recognized multiple NAs of influenza A as well as influenza B NAs and conferred prophylactic protections in mice against H1N1, H5N1, and influenza B viruses. Cryo-electron microscopy structures of two NCS mAbs revealed that they rely on structural mimicry of sialic acid, the substrate of NA, by coordinating not only amino acid side chains but also water molecules, enabling inhibition of NA activity across multiple influenza A and B viruses, including avian influenza clade 2.3.4.4b H5N1 viruses. Our results provide a molecular basis for the broad reactivity and inhibitory activity of NCS mAbs targeting the catalytic site of NA through substrate mimicry.
- Top Cited PapersOpen Access
- 31 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6759) , eadr8382
Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans
A leading HIV vaccine strategy requires a priming immunogen to induce broadly neutralizing antibody (bnAb) precursors, followed by a series of heterologous boosters to elicit somatic hypermutation (SHM) and produce bnAbs. In two randomized, open-label phase 1 human clinical trials, IAVI G002 in the United States and IAVI G003 in Rwanda and South Africa (IAVI, International Aids Vaccine Initiative), we evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens (both trials) and first-boosting immunogens (IAVI G002). The vaccines were generally safe and well tolerated, except that 18% of IAVI G002 participants experienced skin reactions. Priming induced bnAb precursors with substantial frequencies and SHM; heterologous boosting elicited increased SHM, affinity, and neutralization activity toward bnAb development; and elicited antibodies exhibited precise bnAb structural mimicry. The results establish clinical proof of concept that heterologous boosting can advance bnAb precursor maturation and demonstrate bnAb priming in Africa, where the HIV burden is highest.
- 31 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6759) , eadr8382
Top Cited PapersOpen AccessVaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans
A leading HIV vaccine strategy requires a priming immunogen to induce broadly neutralizing antibody (bnAb) precursors, followed by a series of heterologous boosters to elicit somatic hypermutation (SHM) and produce bnAbs. In two randomized, open-label phase 1 human clinical trials, IAVI G002 in the United States and IAVI G003 in Rwanda and South Africa (IAVI, International Aids Vaccine Initiative), we evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens (both trials) and first-boosting immunogens (IAVI G002). The vaccines were generally safe and well tolerated, except that 18% of IAVI G002 participants experienced skin reactions. Priming induced bnAb precursors with substantial frequencies and SHM; heterologous boosting elicited increased SHM, affinity, and neutralization activity toward bnAb development; and elicited antibodies exhibited precise bnAb structural mimicry. The results establish clinical proof of concept that heterologous boosting can advance bnAb precursor maturation and demonstrate bnAb priming in Africa, where the HIV burden is highest.
- Top Cited PapersOpen Access
- 31 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6759) , eadv5572
Precise targeting of HIV broadly neutralizing antibody precursors in humans
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. In a double-blinded, placebo-controlled phase 1 human clinical trial, the recombinant, germline-targeting envelope glycoprotein (Env) trimer BG505 SOSIP.v4.1-GT1.1, adjuvanted with AS01 B , induced bnAb precursors of the VRC01-class at a high frequency in the majority of vaccine recipients. These bnAb precursors, which target the CD4 receptor binding site, had undergone somatic hypermutation characteristic of the VRC01-class. A subset of isolated VRC01-class monoclonal antibodies neutralized wild-type pseudoviruses and was structurally extremely similar to bnAb VRC01. These results further support germline-targeting approaches for human HIV vaccine design and demonstrate atomic-level manipulation of B cell responses with rational vaccine design.
- 31 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6759) , eadv5572
Top Cited PapersOpen AccessPrecise targeting of HIV broadly neutralizing antibody precursors in humans
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. In a double-blinded, placebo-controlled phase 1 human clinical trial, the recombinant, germline-targeting envelope glycoprotein (Env) trimer BG505 SOSIP.v4.1-GT1.1, adjuvanted with AS01 B , induced bnAb precursors of the VRC01-class at a high frequency in the majority of vaccine recipients. These bnAb precursors, which target the CD4 receptor binding site, had undergone somatic hypermutation characteristic of the VRC01-class. A subset of isolated VRC01-class monoclonal antibodies neutralized wild-type pseudoviruses and was structurally extremely similar to bnAb VRC01. These results further support germline-targeting approaches for human HIV vaccine design and demonstrate atomic-level manipulation of B cell responses with rational vaccine design.
- Top Cited Papers
Early influenza virus exposure shapes the B cell response to influenza vaccination in individuals 50 years later